非致命性药物过量后的过量事件、行为健康服务与阿片类使用障碍药物
这项美国队列研究利用2020年1月至2021年12月Medicare按服务付费受益人索赔、人口学与死亡数据,纳入136 762例2020年发生索引非致命性药物过量的≥18岁受益人,随访12个月。结果显示17.4%再次发生非致命性过量、1.0%死于致命性过量,其中72.2%涉及阿片类;仅4.1%接受任何MOUD、6.2%配纳洛酮。配纳洛酮(AOR 0.70;95%CI 0.56-0.89)、接受美沙酮(AOR 0.98;95%CI 0.98-0.99)或丁丙诺啡(AOR 0.99;95%CI 0.98-0.99)的每日百分比、以及行为健康评估或危机服务(AOR 0.25;95%CI 0.22-0.28)均与12个月内致命性药物过量调整后比值降低相关。作者认为需要改善行为健康服务、MOUD和纳洛酮处方等 overdose 预防措施的可及性。
要点
- 136 762例Medicare受益人非致命性药物过量后12个月内,仅4.1%(5556例)接受任何MOUD,6.2%(8530例)配纳洛酮。
- 12个月内17.4%(23 815例)再次发生非致命性药物过量,1.0%(1323例)死于致命性药物过量,其中72.2%涉及阿片类。
- 配纳洛酮处方与致命性药物过量调整后比值降低相关(AOR 0.70;95%CI 0.56-0.89)。
- 接受行为健康评估或危机服务与致命性药物过量调整后比值降低相关(AOR 0.25;95%CI 0.22-0.28)。
- 接受美沙酮(AOR 0.98;95%CI 0.98-0.99)或丁丙诺啡(AOR 0.99;95%CI 0.98-0.99)的每日百分比越高,致命性药物过量调整后比值越低。
适用人群与场景
- 美国Medicare按服务付费受益人,年龄≥18岁,具有国际疾病统计分类第十版临床修改版编码的非致命性药物过量,索引事件发生于2020年。
- 队列中女性80 140例(58.6%),平均(SD)年龄68.2(15.0)岁;西班牙裔5.8%、非西班牙裔黑人10.9%、非西班牙裔白人78.8%;78.9%居住于都市区。
诊断标准与关键阈值
- 非致命性药物过量依据国际疾病统计分类第十版临床修改版编码识别。
研究设计与关键结果
- 研究类型为队列研究,数据来源为美国2020年1月至2021年12月Centers for Medicare & Medicaid Services、Centers for Disease Control and Prevention及其他来源的索赔、人口学、死亡等数据;数据分析于2023年2月至11月进行。
- 共纳入136 762例2020年发生索引非致命性药物过量的Medicare受益人;12个月内23 815例(17.4%)发生至少1次后续非致命性药物过量,1323例(1.0%)死于致命性药物过量,致命性药物过量中72.2%涉及阿片类。
- 12个月内5556例(4.1%)接受任何MOUD,8530例(6.2%)配纳洛酮处方。
- 配纳洛酮处方与12个月内致命性药物过量调整后比值降低相关(AOR 0.70;95%CI 0.56-0.89)。
- 接受美沙酮的每日百分比(AOR 0.98;95%CI 0.98-0.99)和接受丁丙诺啡的每日百分比(AOR 0.99;95%CI 0.98-0.99)均与12个月内致命性药物过量调整后比值降低相关。
- 接受行为健康评估或危机服务与12个月内致命性药物过量调整后比值降低相关(AOR 0.25;95%CI 0.22-0.28)。
证据类型、等级与局限
- 证据类型:队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尽管MOUD和纳洛酮与致命性药物过量风险降低相关,非致命性药物过量后接受这些干预的Medicare受益人比例仍很小。
- 作者认为,需要努力改善行为健康服务、MOUD以及纳洛酮处方和将个体联系至社区医疗场所进行持续照护等过量预防策略的可及性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Recognizing and providing services to individuals at highest risk for drug overdose are paramount to addressing the drug overdose crisis.
OBJECTIVE: To examine receipt of medications for opioid use disorder (MOUD), naloxone, and behavioral health services in the 12 months after an index nonfatal drug overdose and the association between receipt of these interventions and fatal drug overdose.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted in the US from January 2020 to December 2021 using claims, demographic, mortality, and other data from the Centers for Medicare & Medicaid Services, the Centers for Disease Control and Prevention, and other sources. The cohort comprised Medicare fee-for-service beneficiaries aged 18 years or older with International Statistical Classification of Diseases, Tenth Revision, Clinical Modification codes for a nonfatal drug overdose. Data analysis was performed from February to November 2023.
EXPOSURES: Demographic and clinical characteristics, substance use disorder, and psychiatric comorbidities.
MAIN OUTCOMES AND MEASURES: Receipt of MOUD, naloxone, and behavioral health services as well as subsequent nonfatal and fatal drug overdoses.
RESULTS: The cohort consisted of 136 762 Medicare beneficiaries (80 140 females [58.6%]; mean (SD) age of 68.2 [15.0] years) who experienced an index nonfatal drug overdose in 2020. The majority of individuals had Hispanic (5.8%), non-Hispanic Black (10.9%), and non-Hispanic White (78.8%) race and ethnicity and lived in metropolitan areas (78.9%). In the 12 months after their index nonfatal drug overdose, 23 815 beneficiaries (17.4%) experienced at least 1 subsequent nonfatal drug overdose and 1323 (1.0%) died of a fatal drug overdose. Opioids were involved in 72.2% of fatal drug overdoses. Among the cohort, 5556 (4.1%) received any MOUD and 8530 (6.2%) filled a naloxone prescription in the 12 months after the index nonfatal drug overdose. Filling a naloxone prescription (adjusted odds ratio [AOR], 0.70; 95% CI, 0.56-0.89), each percentage of days receiving methadone (AOR, 0.98; 95% CI, 0.98-0.99) or buprenorphine (AOR, 0.99; 95% CI, 0.98-0.99), and receiving behavioral health assessment or crisis services (AOR, 0.25; 95% CI, 0.22-0.28) were all associated with reduced adjusted odds of fatal drug overdose in the 12 months after the index nonfatal drug overdose.
CONCLUSIONS AND RELEVANCE: This cohort study found that, despite their known association with reduced risk of a fatal drug overdose, only a small percentage of Medicare beneficiaries received MOUD or filled a naloxone prescription in the 12 months after a nonfatal drug overdose. Efforts to improve access to behavioral health services; MOUD; and overdose-prevention strategies, such as prescribing naloxone and linking individuals to community-based health care settings for ongoing care, are needed.
参考来源
- Jones CM, Shoff C, Blanco C, et al. Overdose, Behavioral Health Services, and Medications for Opioid Use Disorder After a Nonfatal Overdose. JAMA Intern Med. 2024. PMID: 38884975. doi:10.1001/jamainternmed.2024.1733
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。